<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Standard immunotoxin production procedures using whole IgG as the MoAb moiety yield a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> mixture of 180 kDa, 210 kDa, and 240 kDa immunotoxin species with 1 to 1, 1 to 2, and 1 to 3 MoAb to toxin ratios </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> makes it impossible to precisely deliver a predetermined immunotoxin dose to target cells and impairs the accuracy of pharmacologic studies </plain></SENT>
<SENT sid="2" pm="."><plain>In this report, we describe the preparation and characterization of B43(anti-CD19)-pokeweed antiviral protein (<z:mp ids='MP_0010998'>PAP</z:mp>) immunotoxins containing either one or two 30 kDa <z:mp ids='MP_0010998'>PAP</z:mp> toxin molecules covalently linked to each 150 kDa B43 monoclonal antibody molecule </plain></SENT>
<SENT sid="3" pm="."><plain>Compared to the 180 kDa immunotoxin, the 210 kDa immunotoxin displayed greater in vitro chemical stability, resulted in higher systemic exposure levels in vivo, and was a more effective anti-leukemic agent in a <z:mp ids='MP_0002536'>SCID</z:mp> mouse model of human B-lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Taken together, the results of this study recommend the clinical evaluation of 210 kDa B43-<z:mp ids='MP_0010998'>PAP</z:mp> as a potentially more effective immunotoxin against relapsed B-lineage ALL </plain></SENT>
</text></document>